Target N V Biotech
CIK 1259870 · last filed 2024-11-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ESPR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
PLETTERIJWEG OOST 1, CURACAO
WILLEMSTAD, P8 000000
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Molecular Templates, Inc. (MTEM) Delisted | 10%+ Owner | 0 | $0.00 | $0 | $15.26M | 6 | 2024-11-18 |
| MGNX | 10%+ Owner | 9,079,963 | $2.19 | $19.89M | $10.68M | 3 | 2023-01-23 |
| Radius Health, Inc. (RDUS) Delisted | 10%+ Owner | 8,255,714 | $30.00 | $247.67M | $6.94M | 1 | 2022-01-07 |
| Esperion Therapeutics, Inc. (ESPR) Delisted | 10%+ Owner | 3,652,964 | $3.18 | $11.62M | $22.44M | 3 | 2019-09-06 |
Recent Filings · Page 2 of 2
13 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-09-06 | Esperion Therapeutics, Inc. (ESPR) Delisted | Buy (P) | +160,000 | $5.40M | EDGAR |
| 2019-01-07 | Esperion Therapeutics, Inc. (ESPR) Delisted | Buy (P) | +160,000 | $6.61M | EDGAR |
| 2018-05-22 | Esperion Therapeutics, Inc. (ESPR) Delisted | Buy (P) | +260,000 | $10.43M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.